NCT06593145View on ClinicalTrials.gov

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Acute Lymphoblastic Leukemia (ALL)Mantle Cell Lymphoma (MCL)Large B-cell Lymphoma
Interventions
BIOLOGICAL

FCTX-CL19-1 (Tarcidomgen Kimleucel)

"It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:~* administration route - intravenous~* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight"

Trial Locations (2)

02-097

RECRUITING

Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego - Centralny Szpital Kliniczny, Warsaw

80-214

RECRUITING

Uniwersyteckie Centrum Kliniczne Gdańskiego Uniwersytetu Medycznego - Katedra i Klinika Hematologii i Transplantologii, Gdansk

All Listed Sponsors
lead

FamiCordTx

INDUSTRY